First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

E. G.M. Couturier*, R. Hering, C. A. Foster, T. J. Steiner, F. Clifford Rose

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

SYNOPSISGranisetron (BRL 43694), a selective 5‐HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.

Original languageEnglish
Pages (from-to)296-297
Number of pages2
JournalHeadache: The Journal of Head and Face Pain
Volume31
Issue number5
DOIs
Publication statusPublished - 1 Jan 1991
Externally publishedYes

Cite this